Drug Type Antibody drug conjugate (ADC) |
Synonyms ASG 5ME, ASG-5-ME, ASG-5ME |
Target |
Mechanism CTL4 inhibitors(Choline transporter-like protein 4 inhibitors), Tubulin inhibitors, Tubulin polymerisation inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-Resistant Prostatic Cancer | Phase 1 | US | 01 Oct 2010 | |
Pancreatic Cancer | Phase 1 | US | 01 Jul 2010 | |
Stomach Cancer | Phase 1 | US | 01 Jul 2010 |
NCT01228760 (Pubmed) Manual | Phase 1 | 46 | (dose escalation) | jgiqvdkcbp(qwrjgkndhw) = yegbjxilua mvbcmmmief (dkcamrpdgu ) | Negative | 01 Oct 2019 | |
(dose expansion) | bytlzzknxr(ihwswhmnev) = jqujsurbga mwhmhmlcyu (ijweyrckbk ) View more | ||||||
Phase 1 | 50 | (pancreatic cancer patients (median age 63 years; performance status 0 [40 %] or 1 [60 %])) | rzmbelzkzu(inxfccqayo) = Common drug-related adverse events included fatigue (29 %), nausea (23 %), and vomiting (23 %) for pancreatic cancer patients and fatigue (33 %) and decreased appetite (33 %) for gastric cancer patients euefqckntz (oegvaybqct ) View more | Positive | 01 Jun 2016 | ||
(gastric cancer patients (median age 59 years; performance status 0 [33 %] or 1 [67 %])) |